Brian R. Ferolito

This study conducts a multi-ancestry GWAS meta-analysis of 2.5 million participants to identify genetic variants associated with migraine and link them to biological pathways and therapeutic targets.

This study expands the human plasma proteome analysis using an enhanced SomaScan platform, identifying new genetic associations and disease mechanisms beyond the classical secretome.

The paper uses Mendelian Randomization to predict adverse drug reactions by linking genetic variants to gene expression and protein abundance across large datasets.

This study uses large biobanks to identify gene-trait pairs with causal evidence, rediscover approved drug targets, and develop a predictive model for drug development.

The paper identifies causal protein drivers and drug targets for heterogeneous kidney diseases using proteome-wide Mendelian randomization and EHR data.

This study identifies novel genetic risk variants and potential drug targets for heart failure using GWAS and Mendelian randomization proteomics.